Literature DB >> 19924104

Cyclic nucleotide signaling in polycystic kidney disease.

Xiaofang Wang1, Christopher J Ward, Peter C Harris, Vicente E Torres.   

Abstract

Increased levels of 3'-5'-cyclic adenosine monophosphate (cAMP) stimulate cell proliferation and fluid secretion in polycystic kidney disease. Levels of this molecule are more sensitive to inhibition of phosphodiesterases (PDEs), whose activity far exceeds the rate of cAMP synthesis by adenylyl cyclase. Several PDEs exist, and here we measured the activity and expression of PDE families, their isoforms, and the expression of downstream effectors of cAMP signaling in the kidneys of rodents with polycystic kidney disease. We found a higher overall PDE activity in kidneys from mice as compared with rats, as well as a higher contribution of PDE1, relative to PDE4 and PDE3, to total PDE activity of kidney lysates and lower PDE1, PDE3, and PDE4 activities in the kidneys of cystic as compared with wild-type mice. There were reduced amounts of several PDE1, PDE3, and PDE4 proteins, possibly due to increased protein degradation despite an upregulation of their mRNA. Increased levels of cGMP were found in the kidneys of cystic animals, suggesting in vivo downregulation of PDE1 activity. We found an additive stimulatory effect of cAMP and cGMP on cystogenesis in vitro. Cyclic AMP-dependent protein kinase subunits Ialpha and IIbeta, PKare, the transcription factor CREB-1 mRNA, and CREM, ATF-1, and ICER proteins were upregulated in the kidneys of cystic as compared with wild-type animals. Our study suggests that alterations in cyclic nucleotide catabolism may render cystic epithelium particularly susceptible to factors acting on Gs-coupled receptors. This may account, in part, for increased cyclic nucleotide signaling in polycystic kidney disease and contribute substantially to disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924104      PMCID: PMC3725619          DOI: 10.1038/ki.2009.438

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  73 in total

Review 1.  Tumor reversion: protein kinase A isozyme switching.

Authors:  Yoon S Cho-Chung; Maria V Nesterova
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

2.  Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A.

Authors:  Alexander C Zambon; Lingzhi Zhang; Simon Minovitsky; Joan R Kanter; Shyam Prabhakar; Nathan Salomonis; Karen Vranizan; Inna Dubchak; Bruce R Conklin; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

3.  Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference.

Authors:  Meral Gunay-Aygun; Ellis D Avner; Robert L Bacallao; Peter L Choyke; Joseph T Flynn; Gregory G Germino; Lisa Guay-Woodford; Peter Harris; Theo Heller; Julie Ingelfinger; Frederick Kaskel; Robert Kleta; Nicholas F LaRusso; Parvathi Mohan; Gregory J Pazour; Benjamin L Shneider; Vicente E Torres; Patricia Wilson; Colleen Zak; Jing Zhou; William A Gahl
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

4.  Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells.

Authors:  Jingfei Cheng; Michael A Thompson; Henry J Walker; Catherine E Gray; Gina M Warner; Wei Zhou; Joseph P Grande
Journal:  Exp Biol Med (Maywood)       Date:  2006-03

5.  Dysfunctional cilia lead to altered ependyma and choroid plexus function, and result in the formation of hydrocephalus.

Authors:  Boglarka Banizs; Martin M Pike; C Leigh Millican; William B Ferguson; Peter Komlosi; James Sheetz; Phillip D Bell; Erik M Schwiebert; Bradley K Yoder
Journal:  Development       Date:  2005-12       Impact factor: 6.868

6.  A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues.

Authors:  Lawrence S Kirschner; Donna F Kusewitt; Ludmila Matyakhina; William H Towns; J Aidan Carney; Heiner Westphal; Constantine A Stratakis
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

7.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.

Authors:  Tamio Yamaguchi; Scott J Hempson; Gail A Reif; Anne-Marie Hedge; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2005-11-30       Impact factor: 10.121

8.  Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD).

Authors:  Magdalena Adeva; Mounif El-Youssef; Sandro Rossetti; Patrick S Kamath; Vickie Kubly; Mark B Consugar; Dawn M Milliner; Bernard F King; Vicente E Torres; Peter C Harris
Journal:  Medicine (Baltimore)       Date:  2006-01       Impact factor: 1.889

Review 9.  Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract.

Authors:  George S Baillie; John D Scott; Miles D Houslay
Journal:  FEBS Lett       Date:  2005-04-14       Impact factor: 4.124

Review 10.  Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells.

Authors:  Theresa McSorley; Eduard Stefan; Volker Henn; Burkhard Wiesner; George S Baillie; Miles D Houslay; Walter Rosenthal; Enno Klussmann
Journal:  Eur J Cell Biol       Date:  2006-02-28       Impact factor: 4.492

View more
  37 in total

Review 1.  Mechanisms of nephronophthisis and related ciliopathies.

Authors:  Toby W Hurd; Friedhelm Hildebrandt
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Authors:  Hong Ye; Xiaofang Wang; Megan M Constans; Caroline R Sussman; Fouad T Chebib; María V Irazabal; William F Young; Peter C Harris; Lawrence S Kirschner; Vicente E Torres
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-14

Review 4.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination.

Authors:  Veronika Wetzl; Elisabeth Schinner; Frieder Kees; Lothar Faerber; Jens Schlossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-28       Impact factor: 3.000

6.  Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.

Authors:  Yun-Hee Choi; Akira Suzuki; Sachin Hajarnis; Zhendong Ma; Hannah C Chapin; Michael J Caplan; Marco Pontoglio; Stefan Somlo; Peter Igarashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 7.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

8.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

9.  A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Authors:  Vijayakumar R Kakade; Shixin Tao; Madhumitha Rajagopal; Xia Zhou; Xiaogang Li; Alan S L Yu; James P Calvet; Pankaj Pandey; Reena Rao
Journal:  J Mol Cell Biol       Date:  2016-05-04       Impact factor: 6.216

10.  Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Cibele S Pinto; Archana Raman; Gail A Reif; Brenda S Magenheimer; Corey White; James P Calvet; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2015-08-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.